Results 291 to 300 of about 14,898,836 (369)
PBPK modeling of recombinant factor IX Fc fusion protein (rFIXFc) and rFIX to characterize the binding to type 4 collagen in the extravascular space. [PDF]
Cloesmeijer ME +6 more
europepmc +1 more source
In situ monitoring of bulk photoalignment reveals how molecular weight, azobenzene content, cooling rate, and thickness govern ordering in main‐chain liquid crystalline polymers. Optimized copolymers exceed conventional thickness limits, maintaining stable alignment up to 130 µm with high energy efficiency and reversible optical patterning.
Jaechul Ju +3 more
wiley +1 more source
A study of recurrent life-threatening thrombosis accompanied with the duplication of the factor IX gene. [PDF]
Wei X, Zhang H, Chen W, Zhang J, Dai J.
europepmc +1 more source
A van der Waals optoelectronic synaptic device based on a ReS2/WSe2 heterostructure and oxygen‐treated h‐BN is presented, which enables both positive and negative PSCs through photocarrier polarity reversal. Bidirectional plasticity arises from gate‐tunable band bending and charge trapping‐induced quasi‐doping.
Hyejin Yoon +9 more
wiley +1 more source
Blood coagulation factor IX: structural insights impacting hemophilia B therapy.
Bos MHA, van Diest RE, Monroe DM.
europepmc +1 more source
A novel snake venom C-type lectin-like protein modulates blood coagulation by targeting von Willebrand factor and coagulation factor IX. [PDF]
Zeng FY +5 more
europepmc +1 more source
This review highlights how machine learning (ML) algorithms are employed to enhance sensor performance, focusing on gas and physical sensors such as haptic and strain devices. By addressing current bottlenecks and enabling simultaneous improvement of multiple metrics, these approaches pave the way toward next‐generation, real‐world sensor applications.
Kichul Lee +17 more
wiley +1 more source
Enhanced procoagulant activity of select hemophilia B causing factor IX variants with emicizumab.
Lee K +8 more
europepmc +1 more source
Assessing health care resource use, outcomes, and costs among Medicaid beneficiaries receiving factor IX prophylaxis for hemophilia B. [PDF]
Pauly N +7 more
europepmc +1 more source

